MXCT insider filings
MAXCYTE, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen MXCT transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing by 1 insider — 100,000 shares, $120,780 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 100,000 shares @ $1.21 ($120,780) by Masoud Maher, filed 2026-11-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Masoud Maher — President and CEO, Director | 1 | 1 leg · 100,000 sh · $120,780 | — | — |
Recent insider filings — MAXCYTE, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Masoud Maher — President and CEO, Director | Purchase (P): 100,000 @ $1.21 | EDGAR |
| 2026-06-22 | 4 | Johnston John Joseph — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Hemrajani Rekha — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Erck Stanley C — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Collins Cynthia — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Brooke William W — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Al-Wakeel Yasir B. — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | BALTHROP PATRICK J — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | DOUGLAS RICHARD — Director | Grant/award (A): 30,421 @ $0 · Grant/award (A): 49,579 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Ahuja Parmeet — Chief Financial Officer | Grant/award (A): 187,500 @ $0 | EDGAR |
| 2026-04-10 | 4 | Ahuja Parmeet — Chief Financial Officer | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2026-03-31 | 4 | Masoud Maher — President and CEO, Director | Grant/award (A): 300,000 @ $0 · Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Swirsky Douglas J — CHIEF FINANCIAL OFFICER | Sale (S): 10,142 @ $0.81 | EDGAR |
| 2025-08-27 | 4 | Hemrajani Rekha — Director | Sale (S): 10,684 @ $2.09 | EDGAR |
| 2025-08-13 | 4 | Swirsky Douglas J — CHIEF FINANCIAL OFFICER | Purchase (P): 50,000 @ $1.29 | EDGAR |
| 2025-08-13 | 4 | Masoud Maher — President and CEO, Director | Purchase (P): 75,000 @ $1.37 | EDGAR |
| 2025-08-13 | 4 | Erck Stanley C — Director | Purchase (P): 100,000 @ $1.37 | EDGAR |
| 2025-08-13 | 4 | Brooke William W — Director | Purchase (P): 50,000 @ $1.29 | EDGAR |
| 2025-08-13 | 4 | DOUGLAS RICHARD — Director | Purchase (P): 80,000 @ $1.39 | EDGAR |
| 2025-06-23 | 4 | Johnston John Joseph — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Hemrajani Rekha — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Erck Stanley C — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Collins Cynthia — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Brooke William W — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | Al-Wakeel Yasir B. — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | BALTHROP PATRICK J — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | DOUGLAS RICHARD — Director | Grant/award (A): 29,210 @ $0 · Grant/award (A): 50,790 (derivative) @ $0 | EDGAR |
| 2025-03-20 | 4 | Soleymannezhad Ali — Chief Commercial Officer | Sale (S): 1,211 @ $3.18 | EDGAR |
| 2025-03-20 | 4 | Sandoval David I. — GENERAL COUNSEL | Sale (S): 353 @ $3.18 | EDGAR |
| 2025-03-20 | 4 | Swirsky Douglas J — CHIEF FINANCIAL OFFICER | Sale (S): 6,939 @ $3.18 | EDGAR |
| 2025-03-18 | 4 | Soleymannezhad Ali — Chief Commercial Officer | Grant/award (A): 34,625 @ $0 · Grant/award (A): 138,500 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Sandoval David I. — GENERAL COUNSEL | Grant/award (A): 23,125 @ $0 · Grant/award (A): 92,500 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Swirsky Douglas J — CHIEF FINANCIAL OFFICER | Grant/award (A): 37,500 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Masoud Maher — President and CEO, Director | Grant/award (A): 347,500 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $4.64 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | Sandoval David I. — GENERAL COUNSEL | Sale (S): 4,466 @ $4.54 | EDGAR |
| 2024-12-30 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $4.01 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | Johnston John Joseph — Director | Option exercise (M): 505 @ $2.93 · Sale (S): 505 @ $3.70 · Option exercise (M): 891 @ $2.93 · Option exercise (M): 1,121 @ $1.64 · Option exercise (M): 483 @ $2.93 · Sale (S): 2,495 @ $3.79 · +4 more | EDGAR |
| 2024-11-05 | 4 | Erck Stanley C — Director | Option exercise (M): 47,689 @ $0.04 · Sale (S): 47,689 @ $3.72 · Option exercise (M): 47,689 (derivative) @ $0 | EDGAR |
| 2024-10-30 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $3.72 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-10-16 | 4 | Collins Cynthia — Director | Grant/award (A): 51,679 @ $0 · Grant/award (A): 97,698 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Erck Stanley C — Director | Option exercise (M): 26,082 @ $0.04 · Sale (S): 26,082 @ $3.78 · Option exercise (M): 21,607 @ $0.04 · Sale (S): 21,607 @ $3.71 · Option exercise (M): 26,082 (derivative) @ $0 · Option exercise (M): 21,607 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $3.82 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Soleymannezhad Ali — Chief Commercial Officer | Grant/award (A): 10,400 @ $0 · Grant/award (A): 20,800 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Erck Stanley C — Director | Option exercise (M): 17,922 @ $0.04 · Sale (S): 17,922 @ $4.10 · Option exercise (M): 29,767 @ $0.04 · Sale (S): 29,767 @ $3.97 · Option exercise (M): 17,922 (derivative) @ $0 · Option exercise (M): 29,767 (derivative) @ $0 | EDGAR |
| 2024-08-28 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $4.28 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | Ross Thomas M. — EVP, GLOBAL SALES | Option exercise (M): 15,476 @ $1.64 · Sale (S): 15,476 @ $4.54 · Option exercise (M): 17,857 @ $1.64 · Sale (S): 17,857 @ $4.36 · Option exercise (M): 15,476 (derivative) @ $0 · Option exercise (M): 17,857 (derivative) @ $0 | EDGAR |
| 2024-07-30 | 4 | Johnston John Joseph — Director | Option exercise (M): 3,000 @ $2.93 · Sale (S): 3,000 @ $4.75 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2024-07-10 | 4 | Ross Thomas M. — EVP, GLOBAL SALES | Option exercise (M): 19,802 @ $1.64 · Sale (S): 19,802 @ $4.03 · Option exercise (M): 13,531 @ $1.64 · Sale (S): 13,531 @ $4.03 · Option exercise (M): 19,802 (derivative) @ $0 · Option exercise (M): 13,531 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Johnston John Joseph — Director | Option exercise (M): 5,044 @ $1.64 · Option exercise (M): 4,956 @ $2.93 · Sale (S): 10,000 @ $3.99 · Option exercise (M): 5,044 (derivative) @ $0 · Option exercise (M): 4,956 (derivative) @ $0 | EDGAR |
Recent 8-K events — MAXCYTE, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-16 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-24 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MXCT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs